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Abstract
The ultimate goal of the global programme against lymphatic filariasis is eradication through irrevocable cessation of
transmission using 4 to 6 years of annual single dose mass drug administration. The costs of eradication, managerial
impediments to executing national control programmes, and scientific uncertainty about transmission endpoints, are
challenges to the success of this effort, especially in areas of high endemicity where financial resources are limited. We used
a combined analysis of empirical community data describing the association between infection and chronic disease
prevalence, mathematical modelling, and economic analyses to identify and evaluate the feasibility of setting an infection
target level at which the chronic pathology attributable to lymphatic filariasis - lymphoedema of the extremities and
hydroceles - becomes negligible in the face of continuing transmission as a first stage option in achieving the elimination of
this parasitic disease. The results show that microfilaria prevalences below a threshold of 3.55% at a blood sampling volume
of 1 ml could constitute readily achievable and sustainable targets to control lymphatic filarial disease. They also show that
as a result of the high marginal cost of curing the last few individuals to achieve elimination, maximal benefits can occur at
this threshold. Indeed, a key finding from our coupled economic and epidemiological analysis is that when initial
uncertainty regarding eradication occurs and prospects for resolving this uncertainty over time exist, it is economically
beneficial to adopt a flexible, sequential, eradication strategy based on controlling chronic disease initially.
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Introduction
Given that the health and economic dividends of the current
global campaign to eradicate lymphatic filariasis (LF) by mass drug
administration (MDA) could be large [1,2], a strategy that has as
its ultimate goal the sustained interruption of transmission of this
mosquito-borne infectious disease represents the optimal policy
from a social perspective [3]. This optimality, as for any parasite
control programme, can be tempered, however, by the technical
challenge of maintaining adequate population coverage with
MDA necessary to achieve cessation of transmission within the
currently mooted period of 4 to 6 years and the financial burden of
continuing intervention programmes that target the last few
communities and individuals necessary to meet criteria considered
to be indicative of eradication [3]. Moreover, achieving parasite
eradication implies the need for sustaining control programmes in
order to continue surveillance for residual infections beyond 4 to 6
years [4]. Current scientific understanding of LF eradication is also
hampered by imperfect knowledge regarding parasite transmission
dynamics and endpoint targets [5].
Recent work has also clarified the economic behaviour of
investments in parasite eradication [3,6,7]. A key notion regarding
the desirability of undertaking parasite eradication from this
perspective is that incurring immediate costs is expected to yield
high future long-term benefits. An important caveat of these
appraisals is that most of this work has assumed the technical
feasibility of eradication with little focus given so far to the role of
payoff uncertainty on the choice of optimal strategies. These gaps
in analysis are particularly significant when considering work
carried out in the field of ecological and strategic management,
which shows that when longer-term investment outcomes are
uncertain, it may be optimal to identify and implement effective
strategies over the short term, which can be adapted flexibly to
achieve investment goals as information regarding the attainability
of desired outcomes improves in time [8,9–11].
These considerations suggest that in certain geographical
regions, especially in Sub-Saharan Africa and other areas where
LF endemicity is high and budgetary and capacity constraints
apply, it may be desirable to adopt flexible strategies that first
reduce infection to levels that prevent the occurrence of LF disease
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persists. Although it is not yet known whether such a strategy
would be successful, empirical observations from some MDA trials
have shown that the prevalence of the major chronic disease
manifestations of LF, lymphoedema of the extremities and
hydrocele, can be decreased without reducing transmission levels
to zero [12,13]. Here, we combine epidemiological analyses of
observed data describing the relationship between the overall
prevalence of chronic bancroftian filarial disease and microfilarial
(mf) infection with mathematical model predictions of filariasis
reinfection and economic analysis of MDA interventions, to
estimate and clarify the value of using a threshold infection level
below which LF-induced pathology becomes negligible as a first
stage option in the successful eradication of filariasis.
Methods
(a) Data Sources
Field study data (see Table S1 online) on the association
between the prevalence of Wuchereria bancrofti mf infection and
combined lymphoedema and hydrocele disease rates in filarial
endemic communities were extracted from the published literature
for each of the major endemic regions of Sub-Saharan Africa, Asia
other than India, India, Latin America and the Pacific. Although
this yielded data from 94 separate communities, perusal of the
data showed that adequate data covering the full range of infection
prevalence, especially at lower mf prevalence values, existed only
for Sub-Saharan Africa and India. Our analysis in this study was
therefore by necessity limited to these data compiled from a total
of 76 separate communities from these two regions. Prior to
analysis, all mf prevalence values were standardized to reflect
sampling of 1 ml blood volumes using a transformation factor of
1.95 and 1.15 respectively for values originally estimated using
20 ml or 100 ml blood volumes. These factors were derived using
comparative prevalence data from the parallel application of these
different diagnostic methods on the same individuals [14–18], and
the function, fp~
P
1
ML
P
1
20 or 100
, where P
*
ML is the mean mf prevalence
obtained using the 1 ml blood filtration method and P
*
20 and P
*
100
denote the mf prevalences obtained using 20 ul and 100 ul blood
volumes [5].
(b) Statistical Analysis
The association of mfinfection with chronic LF diseaseis described
and the existence of a threshold in the relationship was examined via
fitting of the following hierarchical logistic dose-response regression
models with and without the specification of a threshold parameter to
the assembled data [19–21]. Model 1 represents the nonthreshold
model and is the familiar basic logistic regression model with an
intercept relating the prevalence of chronic LF disease to observed
community mf prevalence values given by the equation:
log
p
1{p
  
~azbx ð1Þ
The threshold mf prevalence level (t) at which parasitic infection
begins to contribute significantly to the development of chronic
filarial disease is then estimated by fitting the corresponding logistic
dose-response model which incorporates the threshold parameter as
depicted by the equation:
log
p
1{p
  
~
a
azb1 x{t ðÞ
  
for
xƒt
xwt
ð2Þ
where p in both models is the probability of the occurrence of
combined lymphoedema and hydrocele in the community, t is the
threshold value of the risk factor, x (i.e. mf prevalence), a defines the
baseline morbidity prevalence due to non-filarial causes of disease,
and band b1describe the degree of association between infection and
disease with and without the threshold. Model 2 assumes that the risk
of chronic disease is constant below the threshold t and increases
according to the logistic equation above t. Given prevalence data, we
fitted the models assuming binomial errors and obtained parameter
estimates for the data by essentially maximizing the log-likelihood
function [22]:
X
i yi:log piz ni{yi ðÞ :log 1{pi ðÞ ð 3Þ
where yi is the observed disease cases in each community and pi is
the predicted prevalence of disease obtained from equations 1 and
2 respectively, given prevalence of infection, x,a n dni is the sample
size used for assessing disease from each study. We used the gnlr
function in the R software programme, which fits nonlinear
regression equations to data for various common one and two
parameter error distributions, including the binomial distribution,
by minimizing the 2log-likelihood via the Newton-Raphson
iterative method, to fit both models in this study (see details in
[23]). The hypothesis that the threshold model fits the relationship
between community mf prevalence and LF disease prevalence
better than the nonthreshold model is assessed by comparing the
2log likelihood values of each model. The null hypothesis is H0:
t=0 and the alternate hypothesis is H1: t.0. The test statistic is
the likelihood ratio statistic: LR=22(ln L(H0)2ln L(H1)), where
L(H0)i st h e2log likelihood value of the model without a
t h r e s h o l d( m o d e l1 )a n dL(H1)i st h e2log likelihood value of the
model with the threshold level (model 2). The null hypothesis is
rejected if the statistic, LR, is greater than 3.84 (critical value,
a=0.05). Note that although data from two of the major endemic
r e g i o n sa r eu s e d ,w ew e r ea b l et of i tt h em o d e l st oa l lt h ea v a i l a b l e
data and hence, effectively estimate the global threshold value for
the association between mf prevalence and LF chronic disease for
the overall data. Our efforts at fitting the threshold models used in
this study to the data when stratified by endemic regions failed to
converge, most certainly due to the paucity of such data and
especially the restricted ranges of x-values (mf prevalences)
observed for the available studies at the regional level. As in the
case of estimating transmission endpoints [5], this result highlights
the need for generating standardized regional data over the full
range observed in the field (but especially over the lower mf
prevalence range) if these more pertinent regional figures are to be
reliably estimated.
(c) Modelling the impact of MDA interventions
Investigation of the impact of using the estimated mf prevalence
threshold for filarial disease as an intervention endpoint in MDA
programmes was carried out by simulation using EPIFIL, a
deterministic model for LF transmission [5,24,25]. Simulations
predicting annual changes in overall community mf prevalence
following a 5-year intervention programme with either of the two
major MDA regimens (viz. annual single dose diethylcarbamazine
in combination with albendazole (DEC/ALB) or ivermectin in
combination with albendazole (IVM/ALB)) with the assumption
of a pre-control mf prevalence of 10% were compared for
treatment coverages of 65%, 80% and 95%. Drug efficacy values
used in the simulations were: DEC/ALB – 55% worm kill, 95%
mf cured and 6 months mf suppression; IVM/ALB – 35% worm
kill, 99% mf cured and 9 months mf suppression [25].
Filariasis Eradication
PLoS ONE | www.plosone.org 2 August 2008 | Volume 3 | Issue 8 | e2936(d) Marginal cost-effectiveness analysis
This was performed by combining model predictions of the
dynamic impact of an annual IVM/ALB MDA programme given
at 80% coverage in curing individuals of mf with the costs of
carrying out this MDA programme. The major objective of this
analysis was to determine and evaluate the marginal costs of
curing additional individuals to achieve parasite elimination and
eradication of transmission compared to achieving disease control
in a major endemic country. We illustrate the results by basing the
analysis on the real life situation in Tanzania, where the endemic
pre-control LF infection level has been estimated to be around
11.95% mf prevalence [26]. The analysis assumed that the entire
currentpopulationofTanzaniaabove5yearsisatriskandsoeligible
for treatment (corresponding to 28.79 million as estimated in 2002
[27]). Model predictions of the impact of the annual IVM/ALB
MDA givenat80% coverage for a baselinemfprevalenceof 11.95%
were used in the calculations of the mean number of individuals
cured during the MDA programme, with the assumption that LF is
eliminated when mean mf prevalence is reduced to ,0.5% [5]. Two
types of programme costs were estimated and compared. First, the
total programme cost accounting for all resources (including drug
and programmedeliverycosts)usedincarryingoutanannualMDA,
which was conservatively assumed to be around $0.70 for treating
one individual [28,29]. Second, government costs, defined as the
financial costs of all inputs paid for directly by the Ministry of Health
excluding any donations to the programme such as donated drugs.
We estimated this cost to be around $0.53 per treated individual
using the estimates given in Ramzy and colleagues [29]. The former
approach isusefulinassessingthe allocation of programmeresources
and their opportunity costs, i.e. determining whether these resources
could be used more productively elsewhere, whereas the latter cost
estimates are helpful to national planners in assessing programme
affordability. Numbers of individuals cured and all costs were
discounted at 6% [28].
(e) Modelling the cost of sequential-decision approaches
based on chronic disease control
We evaluated the strategic value of implementing a sequential
decision approach to LF eradication in which chronic disease
control is first achieved followed by additional MDAs to achieve
parasite eradication when information regarding the feasibility of
eradication improves over time, by undertaking a scenario-based
analysis of the comparative costs of a programme aimed from the
beginning solely at eradication versus a two-staged strategy based
initially on disease control as follows. The analysis was based on
EPIFIL predictions of the number of annual MDAs required to
meet the endpoints of these scenarios given the baseline endemic
mf infection prevalence level of 11.95% estimated for Tanzania
and a drug coverage level of 80%.
First, we considered the cost of the base strategy in which we are
certain that parasite eradication can be achieved in 10 years. The
expected present cost (EPC) of this strategy is given by:
EPC1~C1z
X 10
t~2
Ct
1zr ðÞ
t{1 ð4Þ
where C1 is the estimated cost of MDA in year 1 (calculated at a
per capita cost of $0.70 per person (see above)), Ct denotes the cost
of MDA for each of the years 2 to 10, and r represents the discount
rate (6% as above).
In scenario two, we assume that information regarding the
feasibility of eradication becomes clear only some time in the
future, say in year 5 following repeated annual MDAs (i.e. at the
disease control threshold) when we will either know with a high
probability, p=0.90, that eradication is possible by year 10 in
which case we will continue with 5 more annual MDAs to achieve
eradication or we will know with a probability 12p=0.10 that
eradication is not achievable with the current knowledge and/or
technology. At this point, we may abandon the goal of eradication
and switch to long-term control, i.e implement treatment every 10
years (calculations shown here for at least up to 35 years), thus
allowing flexibility to wait for further information to resolve
uncertainty to aide making the choice that maximizes the value
and minimizes loss from the MDA programme (as a result of
reinfection to baseline levels if eradication is not achieved).
In scenario 3, we model a situation similar to scenario 2, but
instead of considering that eradication is never possible, we
consider that uncertainty in present knowledge and technology is
likely to be resolved by years 10 and 15 post initial MDA, when
the probability of eradication will occur at p=0.90, and
eradication then given model predictions is expected to be possible
with an extra three years of annual MDA following disease control
with 5 annual MDAs initially.
The EPC of scenario two is hence given by:
EPC2~C1z
X 5
t~2
Ct
1zr ðÞ
t{1 zp
X 10
t~6
Ct
1zr ðÞ
t{1 z
1{p ðÞ
X
t~15,25,35
Ct
1zr ðÞ
t{1
ð5Þ
where C1, Ct and r are described as above and p denotes the
probability that eradication is possible (p=0.90).
For scenario three, in which disease control is followed by the
switch to eradication when information regarding the feasibility of
eradication becomes better known either in year 10 or year 15, the
EPC for the year 10 case is given by:
EPC3a~C1z
X 5
t~2
Ct
1zr ðÞ
t{1 zp
X 10
t~6
Ct
1zr ðÞ
t{1 z
1{p ðÞ
X 13
t~10
Ct
1zr ðÞ
t{1
ð6Þ
and for the year 15 case by:
EPC3b~C1z
X 5
t~2
Ct
1zr ðÞ
t{1 zp
X 10
t~6
Ct
1zr ðÞ
t{1 z
1{p ðÞ
X 18
t~15
Ct
1zr ðÞ
t{1
ð7Þ
with variables as described before.
Results
Figure 1 depicts the data collated from all relevant published
studies available from Sub-Saharan Africa and India on the
association between the community prevalence of LF infection and
the corresponding prevalence of chronic disease (n=76). Despite
the presence of some between-region geographic variation, the
scatterplot depicted in the figure shows that there is a global
occurrence of an overall positive but non-linear association
between chronic disease attributed to LF and mf infection, with
disease apparently constant up to a threshold mean mf prevalence
level and then increasing positively. Such a disease-infection
Filariasis Eradication
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of an infection dose response function whereby in communities
with low mf prevalence the observed disease may be due to causes
other than filariasis while disease attributable to filarial infection
develops only above a specific mf threshold [22]. Table 1 shows
the results of the statistical fits of models 1 and 2 to the data, and
supports the visual impression from figure 1 of the existence of an
‘‘average’’ mf threshold in the development of LF chronic disease
in the present data. The curve in the figure portrays the
predictions of the logistic regression-based dose response model
incorporating a threshold (model 2), and indicates that the pattern
illustrated by the data for the occurrence of a threshold dependent
dose-response in the association between LF infection and disease
is adequately described by this model (see Text S1 and Figure S1
online for details of goodness of fit of the model). This result
indicates that a threshold mf prevalence value that could be used
as a target for suppressing formation of filarial disease may lie in
the region of 3.55% (95% confidence limits: 2.35–4.75) at the 1 ml
blood sampling volume scale, with the caveat that there could be
regional differences in the value of this threshold among endemic
communities based on the peculiar features of local mosquito-
vector parasite interactions. The results also indicate that on
average up to 1.07% of the observed lymphoedema and hydrocele
cases may be non-filarial in aetiology [30].
Figure 2A shows how predictions of a mathematical model of
filariasis transmission [24,25,31] allow an examination of the
usefulness of implementing a 5-year MDA strategy with DEC/
ALB or IVM/ALB that has as its target either parasite elimination
and eradication (set to be around 0.5% mf prevalence here [5]) or
disease control (3.55% mf prevalence). The simulations in the
figure are all based on a moderately high overall community pre-
control mf prevalence of 10% (at the scale of 1 ml blood sampling
volume), and for each treatment regimen are illustrated for
coverage values of 65%, 80% and 95% (portrayed by curves going
from bottom to top respectively for each drug regimen). The
results indicate that while neither MDA regimen achieved the
parasite elimination target for all the three treatment coverages
considered, both achieved the disease control target of 3.55% mf
prevalence before 5 years. This was true even in the case of the less
effective IVM/ALB regimen given at the lowest MDA coverage of
65%. An additional feature of the results is that following the end
of the treatment programme, the rates of rebound of infection
(given that transmission has not been interrupted) are also
predicted to be slow. For the IVM/ALB regimen with only 65%
population coverage, infection levels reduced to ,2.35% are
predicted to remain under the disease control threshold for at least
7 years after cessation of the 5-year intervention programme. At
higher coverages, and for the more effective DEC/ALB regimen,
infection levels remained below the threshold level for more than
10 years (Fig. 2A).
This effect of the achieved post-control mf prevalence following
MDA on the rate of return of infection prevalence to pre-control
equilibrium values is more clearly shown in Figure 2B, and
indicates how this relationship can be used to guide the setting of
the mf prevalence target for long-term disease control. Thus, the
numerical projections in Figure 2B indicate that reducing mf
prevalence to below 2.35% (i.e. below the lower 95% CL value of
the disease control threshold (Table 1)) may maintain infection
levels below the disease incidence threshold of 3.55% mf
prevalence for up to as long as ,10 to 12 years before repeat
MDAs will be required to depress infection again to sustain the
control of disease. This dynamical epidemiological result clearly
makes disease control both a feasible and sustainable option in
endemic communities.
Table 2 summarizes and compares the predicted average and
marginal costs of the annual IVM/ALB MDA programme (80%
coverage) in curing individuals of mf to achieve LF elimination in
Tanzania. The results show that for both types of cost estimations
(the total economic and the financial costs of programme delivery
only by the Ministry of Health), the average cost per individual
cured of mf to achieve disease control will be moderately low
whereas the average and marginal cost of curing additional
individuals at each subsequent MDA round until transmission
elimination is achieved will increase steeply. This is because, as the
number of MDA rounds increase (an additional 5 years of MDA is
predicted to be required to achieve transmission elimination as
compared to 5 years of MDA in total to achieve long-term disease
control, ie., by achieving mf prevalence reduction to 2.35%
following annual MDA (see above)), a progressively decreasing
proportion of individuals are cured at the same fixed outlay for
implementing the annual mass treatment programme. For
Figure 1. The association between prevalence of Wuchereria
bancrofti microfilarial infection and prevalence of combined
lymphoedema and hydrocele disease in filarial endemic
communities from Sub-Saharan Africa (#) and India (N). Field
study references (n=76) are given in Table S1 online. All mf prevalence
values have been standardized to reflect sampling of 1 ml blood
volumes (see text). The curve shows the best-fit logistic regression-
based dose-response model incorporating a threshold parameter
(equation 2) for the overall data with estimated values for a and t of
1.07% (95% confidence limits (CLs): 0.54 to 1.60%) and 3.55% (95% CLs:
2.35 to 4.75%), respectively. Details of goodness of fit of the model are
given in Supplemetary figure 1 online.
doi:10.1371/journal.pone.0002936.g001
Table 1. Parameters and negative log-likelihoods for the
logistic dose-response models with and without a threshold
fitted (see text) to the mf – LF chronic disease prevalence data
(n=76).
Value of:
2log
likelihood LR
1
Model abt
1 1.02 (0.096) 0.27 (0.005) - 2720.635
2 1.07 (0.530) 0.34 (0.008) 3.55 (1.196) 2230.311 15.817
2
Figures in parentheses denote the standard errors estimated for each
parameter.
1Likelihood ratio statistic (see text).
2p,0.0001.
doi:10.1371/journal.pone.0002936.t001
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over the additional 5 MDAs to meet the target of transmission
elimination as compared to the 2.5 million cured over 5 years to
achieve long-term disease control (Table 2). Because the number
of MDA rounds required to achieve disease control is smaller than
that required to achieve transmission elimination (indeed, in
general this will take half the time required for parasite elimination
(results not shown)), the marginal cost of achieving disease control
will also be considerably smaller compared to that for achieving
parasite elimination. The analysis presented here used a very
conservative cost of $0.70 in the case of the total economic cost
approach and $0.53 in the case of the Government cost method to
treat one individual [28,29,32,33]; increasing this cost will only
further amplify the present findings.
Indeed, in cost-effectiveness terms, the declining number of
additional individuals cured as annual MDA proceeds compared to
the increasing marginal cost of curing these individuals from the
additional cycles of MDA suggests that maximal benefits may occur
at less than 100% parasite control or parasite elimination. This is
highlighted in Figure 3, which graphically compares the expected
effectiveness and costs of the annual MDA programme to eliminate
LF in Tanzania. Figure 3 shows that the maximal cost-effectiveness
of the programme could occur at 85% parasite control following 3
annual MDAs. This is closer to the predicted 5 cycles of annual
MDA required to achieve long-term disease control for this country
(Table 2) in contrast to the 10 annual cycles needed to achieve
parasite elimination or 100% parasite control, and further supports
the soundness of a diseasecontrol option asa first phase intermediate
objective in efforts to eradicate LF.
This incremental role of controlling disease first in LF eradication
is reinforced by the estimates of the expected present costs (EPCs) of
LF eradication strategies for the Republic of Tanzania with and
without a flexible sequential-decision option based on exercising
disease control option, shown in Table 3. The number of years
needed to achieve LF disease control or/and eradication were based
on EPIFIL model predictions as described in Methods,w h i l e
similar treatment costs and discount rates as utilized in the marginal
cost-effectiveness analysis were used in the analysis for comparative
purposes. The results depict that the EPCs of strategies that contain
the flexibility of switching between disease control and eradication
are lower than that of an eradication strategy in which no flexibility
to either switch to disease control if eradication is not feasible or to
embark upon eradication after disease control when eradication
becomes favourable exists. Since the EPCs of the flexible strategies
are lower than that of the inflexible eradication strategy, it is clear
that such strategies should be preferable highlighting their optimality
when uncertainty regarding eradication occurs. Indeed, the results
show that switching to long-term disease control from year 5 (MDAs
given every 10 years following an initial 5 annual MDAs to achieve
disease control: Strategy 2) can be the cheapest intervention option
for LFiferadication can neverbeachieved (Table 3),while thelower
EPCs of Strategies 3a & b compared to Strategy 1 highlight the costs
which can be saved by waiting for better information regarding the
feasibility of eradication before switching to eradication from disease
control.Thevalue ofincludingsuchflexibilities inthe LFeradication
programme for the republic of Tanzania is given by option value
figures depicted in Table 3, and indicates that including flexible
decision-making basedinitiallyon diseasecontrolcanyieldsavingsof
between US$ 3.3 to 5.0 million depending on the feasibility of
eradication (from never (Strategy 2) to waiting to switch to
eradication at different times when knowledge and technology
improves (Strategies 3a & 3b)).
Figure 4 shows the relationship between the probability of
eradication (the lower this probability the higher the uncertainty
regarding the feasibility of eradication) and the EPC values of
Strategies 3a and 3b. The results show that as uncertainly
regarding eradication increases the EPCs of these strategies will
Figure 2. (A) Simulation results showing annual changes in overall
community mf prevalence (scaled to 1 ml blood sampling volume)
predicted by a deterministic model for filariasis transmission following a
5-year annual intervention programme with either the DEC/ALB (solid
lines) or IVM/ALB (dashed lines) drug regimen. Initial community mf
prevalence was set at 10%, and for each regimen predictions are shown
for treatment coverages of 65%, 80% and 95% (portrayed by curves
going from top to bottom respectively for each regimen). Upper
horizontal dashed line shows the disease control mf threshold of 3.55%,
while the lower line depicts the parasite elimination threshold of 0.5%
mf prevalence. All figures are given at the scale of 1 ml blood sampling
volume. Drug efficacy values are as given the text. (B) Numerical
projections (dashed curves) of changes in LF infection prevalence (Mf %
at 1 ml blood sampling scale) following different levels of reduction
from initial equilibrium infection prevalence induced by annual MDA, as
predicted by the EPIFIL model. Note that the greater the reduction of
initial prevalence to below the mean disease threshold of 3.55% mf
prevalence (solid horizontal line), the longer it will take to rebound to
this threshold. For example, a reduction to a mf prevalence of 2.175%
following annual MDA (second dashed curve from the bottom) will take
up to 12 years to rebound to the disease incidence threshold.
doi:10.1371/journal.pone.0002936.g002
Filariasis Eradication
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of flexibility using chronic disease control should be even more
preferable when uncertainty regarding eradicability is high. For
example, when uncertainty regarding eradication is even moder-
ately high, say at the probability of eradication of only p=0.70,
the costs saved (or option value of) employing Strategy 3a over the
inflexible Strategy 1 can be as high as US$10.0 million and for
Strategy 3b even higher at US$12.0 million. Note that because of
the effects of discounting, Strategy 3b will always be better value
than Strategy 3a as the extra costs related to switching to
eradication occurs 5 years later compared to the case with the
latter strategy (Table 3).
Discussion
This study set out to use a combined epidemiological and
economic approach in order to evaluate the possibility of estimating
and setting an infection threshold that achieves control of LF-related
disease as a rational and feasible first stage target for LF eradication
programmes. Our analyses show that not only may such a threshold
exist but alsothatthisendpoint islikelyto besustainableowing tothe
slow rebound of infection following MDA (principally as a result of
the long life span of the adult parasite [24]). The results also reveal
that a third epidemiological factor which may make an intervention
strategy aimed at controlling LF morbidity as an intermediate step
on the path to parasite eradication attractive to policy makers and
health care planners in developing countries – namely that disease
controlthresholdscangenerallybeachievedinhalfthetimerequired
for accomplishing transmission elimination. This is shown to be the
case even if the long-term disease control mf prevalence target is set
to be lower(eg,2.35%) than the infection threshold (3.55%) at which
disease develops in communities. From the perspective of national
health agencies responsible for implementing and sustaining MDA
programmes, this finding highlights the feasibility of achieving
disease control readily compared to transmission elimination,
especially when model predictions and available data [13,34–37]
suggest that even when high population coverage is achieved the
duration of annual MDA necessary to stop transmission can be
expected to extend beyond 7 years inthe many endemic areas where
the baseline mf prevalence is equal to or greater than 10% [5,25].
Note that our estimate of the disease control threshold was
technically made possible only via synthetic epidemiological
analysis based on using all the available published data from only
two of the major LF endemic regions. Given the geographic
variation in the data used to construct Figure 1 and lack of
adequate information within and across many other LF endemic
areas, this estimated disease threshold could in reality vary
between regions. However, as noted above, the paucity of regional
data describing the mf and disease prevalence relationship
Table 2. Predicted average and marginal costs of an annual IVM/ALB MDA programme to control disease or eliminate LF
transmission in the Republic of Tanzania.
Programme Cost (US$)
3
No. of individuals
cured of mf
Ratio of total cost to no. of
individuals cured of mf (US$
per individual)
3
Ratio of Govt cost to no.
of individuals cured of mf
(US$ per individual)
4
1. Disease control (5 years of annual MDA)
1 89,949,942 2,467,830 36.45 27.60
2. Transmission Elimination (10 years of annual MDA)
2 157,165,771 2,790,395 56.32 42.65
3. Increment (of Programme 2 over Programme 1)
5 67,215,829 322,565 208.38 157.77
1Represents a programme targeted at disease control assumed to occur when the mf prevalence is reduced long-term (for at least 10 years) to below 3.99% (figure 2a).
For a baseline prevalence of 11.95% mf prevalence, it is predicted to take up to 5years of MDA with IVM/ALB to reduce infection prevalence to 2.3% to achieve this
objective at 80% coverage.
2Represents a programme to eliminate parasite transmission assumed to occur when the mf prevalence is reduced to just below 0.5%. For a baseline prevalence of
11.95% mf prevalence, it is predicted to take up to 10 years of MDA with IVM/ALB to achieve this target at 80% coverage.
3The full economic cost of the programme, including the cost of donated drugs and programme delivery costs borne by the Government estimated at $0.70 for treating
each individual.
4Excludes the cost of donated drugs. Estimate of drug costs to total programme cost obtained from ref (24.2%) is used in calculating only the additional Government
cost involved in delivering the MDA programme. Effectively, this decreases the per capita cost of treating an individual from $0.70 per individual for the total cost
estimation to $0.53 per individual for the Government costs only estimation.
5Addition individuals cured of mf and the total and average marginal costs of curing these individuals to achieve parasite transmission elimination from a programme
targeted at disease control.
doi:10.1371/journal.pone.0002936.t002
Figure 3. Marginal effectiveness (numbers of individuals cured
of mf) and costs of annual mass IVM/ALB chemotherapy
against LF in Tanzania and the determination of the optimal
level of parasite control. Simulations of costs and effectiveness are
based on the cost and demographic details given in table 2 and the
impact of annual IVM/ALB mass treatment (at 80% coverage) on the
prevalence of LF infection predicted by EPIFIL assuming the baseline Mf
prevalence of 11.95% (at 1 ml blood sampling volume) in Tanzania.
Annual costs and effectiveness are both expressed as a fraction of their
total discounted figures following 10 years of intervention (table 2). The
results show that the maximum number of individuals cured of mf per
unit cost occurs at 85% parasite control following 3 years of annual
MDA closer to achieving the long-term disease control target of 2.35%
(see text) than the target of 100% parasite control or elimination.
doi:10.1371/journal.pone.0002936.g003
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precludes the estimation of pertinent region-specific figures and
determination of whether the mf threshold estimated here is valid
for all endemic areas that have or will soon participate in national
MDA programmes. This conclusion, as highlighted also for the
estimation of transmission endpoints in LF [5], signifies the need
for collecting more reliable standardized data spanning the natural
range of prevalences observed in the field at the regional level. In
the meanwhile, given that data from Sub-Saharan Africa were
used in the estimation of the disease threshold value here, we
suggest that the present results for the Republic of Tanzania are
unlikely to be severely influenced by this issue.
The economic analyses carried out in this study have yielded
two major insights regarding the choice of optimal eradication
strategies for LF hitherto not fully recognized. First, marginal cost-
effectiveness analysis has demonstrated that when epidemiological
results are combined with economic rationalities, disease control as
a first stage target is likely to be attractive to policy makers as a
result of the far higher marginal cost that arises from having to
cure additional individuals in order to stop parasite transmission
completely compared to controlling disease. Coupled with
relatively low cost social efforts that emphasize local hygiene to
prevent and treat forms of chronic morbidity such as lymphoe-
dema of the extremity [38], this important outcome suggests that
the decision to undertake parasite eradication must take explicit
account of the opportunity cost of eradication, especially when
budgetary and capacity constraints exist within the health systems
expected to implement and sustain mass intervention programmes.
Indeed, our analysis shows that the relationship between the
marginal social benefits and costs of annual LF MDA is such that
theoptimallevelofparasitecontrolmaybeclosertothatachievedby
disease control compared to parasite elimination. This result is
tempered by the technical feasibility of achieving parasite elimina-
tion [3], but it does indicate that given the slow expected rebound of
infection when parasite transmission is reduced but not eliminated,
humanand financialresourcesthat wouldotherwisebeexpendedfor
continuation of MDA and infection surveillance during the period of
low reinfection could be spent more beneficially on economic and
social development oftarget populations(better sanitation, improved
health and educational facilities, increased income-generating
options). In purely economic terms, these findings pertaining to
both the feasibility and opportunity cost of achieving parasite
elimination underscore the well-known principle that opting for first-
best efforts, such as eradication or elimination, is unlikely to be
attainable in a second-best world [39–41]. Instead, they suggest that
Pareto optimality under these circumstances may be better achieved
by opting for second-best strategies, such as disease control, ie.,
optimal policy must crucially account for the feasibility of
implementing proposed strategies [40–42].
Although the results of the marginal cost-effectiveness analysis
carried out here has shed light on issues underlying the economic
optimality of undertaking disease control versus eradication,
particularly that social welfare may be maximized at levels of
parasite control below eradication levels, it is restricted in its scope
as it does not address the continuous nature of investment that
would be required to maintain disease control (which clearly
makes eradication optimal if technically feasible [43,44]) and the
issue of uncertainty in the possibility of achieving eradication. The
latter is an overriding issue for the development of optimal LF
intervention strategies given the current imperfect scientific
knowledge regarding transmission endpoint values, the duration
and intensity of treatments required to achieve parasite elimina-
Table 3. Expected Present Costs of LF eradication strategies for the Republic of Tanzania with and without sequential-decision
making flexibility based on exercising chronic disease control options.
Strategy
1 Design EPC
2 Option Value
3
S1 Inflexible: 10 year annual MDA 157,165,771
S2 Flexible: Switch to long-term disease control after 5 years of annual MDA when it
becomes evident eradication is not possible
152,110,572 5,055,199
S3a Flexible: Switch to eradication with 3 extra annual MDAs from year 10 following disease
control with 5 initial annual MDAs
153,822,682 3,343,089
S3b Flexible: Switch to eradication with 3 extra annual MDAs from year 15 following disease
control with 5 initial annual MDAs
152,968,795 4,196,976
1Denotes the three different scenarios described in detail in the text.
2Expected Present Cost of each strategy in US$.
3The difference between the EPCs of flexible strategies 2 to 3 over strategy 1 represents the value (costs saved here) of retaining the option to switch between
eradication and disease control depending on the state of eradication feasibility.
doi:10.1371/journal.pone.0002936.t003
Figure 4. The relationship between Expected Present Costs
(EPCs) of implementing Strategies 3a (S3a) and 3b (S3b) (see
text) and the probability of LF eradication for the Republic of
Tanzania. The lines show that as the uncertainty regarding the
feasibility of eradication increases (probability of eradication becomes
lower) the expected costs of these flexible strategies decline
dramatically.
doi:10.1371/journal.pone.0002936.g004
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emergence of drug resistance in treated worm populations
[5,25,45,46], and problems associated with organizational capac-
ities and finances in many endemic countries that are likely to
affect the adequate implementation of long-term interventions.
We have attempted to address these issues via expected cost
comparisons of an intervention aiming solely at eradication with
those combining disease control with wait options to switch to
eradication depending on when knowledge and/or technology for
achieving eradication becomes more certain. Our primary finding
is that when longer-term uncertainty about programme payoffs
exists, there is value in developing and implementing flexible,
dynamic approaches that focus on identifying and implementing
optimal shorter-term strategies (such as disease control considered
here) which can be adjusted (switched to eradication or even long-
term disease control) according to future scientific progress [9–11].
Our analysis illustrates that this is basically because any long-term
decision taken now under uncertainty has an opportunity cost in
that it eliminates the option of waiting for further information and
hence the possibility of making better loss minimizing decisions
later. We have shown that this option value for flexible sequential-
decision making under eradication uncertainty can be large
depending on the nature and timing of flexibility and degree of
uncertainty (Table 3); indeed we calculate that for moderate
uncertainty (probability of eradication=0.70), implementing
flexible LF eradication strategies based on chronic disease control
initially can yield cost savings (or option values) of up to
US$12.0 million over the cost of implementing the alternate
inflexible strategy focused solely on eradication currently being
recommended for the Republic of Tanzania (Fig. 4).
Analyses carried out in this study and the considerations above
suggest that although the aim of parasite eradication by the
current global initiative against LF is sound, laudable and likely
achievable in areas of low to moderate endemicity, a strategy
focused primarily or solely on eradication in every location,
especially those where the baseline mf prevalence is high, could be
sub-optimal. Rather, we have shown that under those circum-
stances and especially when there is initial uncertainty and there
exists a possibility that knowledge and/or technology for effectively
achieving eradication will improve with time, it is more desirable
and cost-efficient to achieve disease control at the first instance.
This can then be followed by a decision to intensify eradication
attempts once baseline mf prevalences are reduced below the
disease control threshold of 3.55%. In this respect, it is important
to acknowledge how the prospects of harnessing existing and new
knowledge regarding chronic LF morbidity control and transmis-
sion interruption, particularly the demonstrated value of local
hygiene in treating lymphoedema [38,47,48], confirmation that
MDA prevents and possibly reverses pre-existing LF-related
lymphedoema and/or hydrocele [13], and a more rapid
achievement of transmission cessation by adding vector control
such as insecticide treated bed nets to MDA [49,50], into the
global strategy are likely to improve the feasibility of effective and
sustainable parasite eradication. It is also instructive to note that
morbidity due to blindness was achieved much more readily than
transmission interruption in the case of the intervention pro-
gramme against the closely related filarial disease, onchocerciasis,
in both Africa and Latin America [51,52]. Finally, it is important
to recognize that parasite management programmes are embed-
ded within and affected by real-world social-ecological systems
[53,54]. Thus, implementing a sequential approach will support
effective management of these programmes by allowing the
incremental achievement of success by health agencies with its
attendant boosting of organizational morale, accountability,
learning and competency [55,56].
We conclude that these results indicate that current debates
about disease control and eradication must include and take
careful account of these factors so that richer and more
comprehensive evaluative frameworks than simple epidemiological
and investment appraisals can be developed and applied to
achieve the control or elimination of human infectious diseases,
particularly those occurring in the developing world.
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